«
Reply #1 on: April 19, 2022, 09:40:21 pm »
In the New England Journal of Medicine Journal Watch (April 15, 2022) there is a "Report from the 2022 American Academy of Neurology Annual Meeting" that includes this as one of several highlighted presentations:
COVID-19 RATES HIGH AMONG VACCINATED MS PATIENTS ON CERTAIN DISEASE-MODIFYING THERAPIES
Patients with multiple sclerosis (MS) who are fully vaccinated against COVID-19 and taking the disease-modifying drug ocrelizumab have higher rates of SARS-CoV-2 infection and hospitalization than those receiving other disease-modifying therapies, according to a new study. Patients taking fingolimod also had a higher rate of infection.
Using U.K. health databases, researchers assessed the incidence of SARS-CoV-2 infection and COVID-19-related hospitalization among roughly 38,000 patients with multiple sclerosis who were receiving disease-modifying therapies and had received two doses of COVID-19 vaccine.
From December 2020 to January 2022, the incidence of SARS-CoV-2 infection was 24% for patients who were taking ocrelizumab, 22% for fingolimod, and 11% to 16% for other disease-modifying therapies. Among those infected, the hospitalization rate was highest for ocrelizumab, at 7%, followed by 4% for fingolimod and 1% to 4% for other disease-modifying therapies.
Our clinician-guide, Dr. Seemant Chaturvedi, said: "This study provides thought-provoking data on the potential efficacy of COVID-19 vaccinations for certain MS patients on disease-modifying therapies."
« Last Edit: April 19, 2022, 09:42:51 pm by agate »
MS Speaks--online for 17 years
SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.